Blocking the PD‐L1 and PD‐1 interaction with immune checkpoint inhibitors, such as anti‐PD‐1 and CTLA‐4, allows T cells to recognize and effectively eliminate tumour cells.19, 20. This evidence concerns the gene CTLA4 and neoplasm.